Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPOPEX open-label extension of EPITOPE: long-term Viaskin Peanut in peanut-allergic children
2018-003323-10Phase 3Completed
- Sponsor
- DBV Technologies
- Start
- Nov 2019
- Modality
- Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of DBV712 Viaskin® in peanut allergy (2 arms), sponsored by DBV Technologies. Primary endpoint: Sustained clinical benefit after 1, 2 and 3 years. Started Nov 2019; status: completed.
02
Drugs
DBV712 Viaskin®
03
Conditions
peanut allergy
Beyond the preview
Go deeper on 2018-003323-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003323-10.